Trial Profile
A Phase I Open-label, Multicenter Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of PLB1003 in Patients With ALK-positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Jan 2022
Price :
$35
*
At a glance
- Drugs PLB 1003 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man
- Sponsors Beijing Pearl Biotechnology
- 02 Mar 2020 Planned End Date changed from 30 Jun 2019 to 30 Dec 2021.
- 02 Mar 2020 Planned primary completion date changed from 30 Jun 2018 to 30 Dec 2020.
- 10 Sep 2019 Interim results (as of 31 August 2018; n=21) assessing safety and tolerability of PLB1003 in patients with non-smallcell lung cancer, presented at the 20th World Conference on Lung Cancer.